Home > Boards > US Listed > Biotechs >

Avid Bioservices Inc. (CDMO)

CDMO RSS Feed
Add CDMO Price Alert      Hide Sticky   Hide Intro
Moderator: TekNuLoof, cjgaddy, stoneroad, biopharm, 4OurRetirement
Search This Board: 
Last Post: 4/24/2019 4:22:23 PM - Followers: 833 - Board type: Free - Posts Today: 0


Avid Bioservices, Inc. (Nasdaq “CDMO”), Tustin CA. http://www.avidbio.com
Four Avid Fact Sheets a/o 8-9-18: https://avidbio.com/publications/brochures/
Avid Bioservices is a CDMO committed to improving the lives of patients by manufacturing products derived from mammalian cell culture for the biotechnology & biopharmaceutical industries. Services include cGMP clinical & commercial product manufacturing, purification, bulk packaging, stability testing & regulatory strategy, submission, and support. The company also provides a variety of process development activities, including cell line development & optimization, cell culture & feed optimization, analytical methods development, and product characterization.

UPCOMING EVENTS: http://ir.avidbio.com/events-and-presentations
Sep6/4:15-4:40pmET/R.Lias: H.C. Wainwright 20th Annual Global Investment Conf. (NYC) webcast: https://tinyurl.com/y8z5h8ns
Sep10/After: FY'19Q1 (qe 7-31-18) Financials & Conf. Call - CC Transcript: https://tinyurl.com/y8oc6hx8
Sep18/9:55amET/R.Lias: Janney Montgomery Scott 2018 Healthcare Conf. (NYC) webcast: https://tinyurl.com/yb5kp4es
Sep27-28/Booth918: Contract Pharma’s 17th Annual Contracting & Outsourcing Conf.”, NewBWK NJ http://conference.contractpharma.com
Oct4 10amPT: Avid's 2018 Annual Shareholder’s Mtg (Tustin) - Lias' Slideshow/Atendee Report: https://tinyurl.com/yctfzhlb
Dec10/AfterHrs: FY'19Q2 (qe 10-31-18) Financials & Conf. Call Transcript: https://tinyurl.com/y9n374kp

Feb 13: SoCalBio Mini Conference - Working with the Best CROs, UCLA California NanoSystems Inst.
...William Leonardi(ProjMgr) pres., “The Difficult Decision - Identifying What's Important for CDMO Selection”

Mar11-14/Booth401: BioProcess Intl. US West (BPI West), Santa Clara
...Gene Yoshioka(SrDirMFG)/Panel, “Flexible & Smart Facilities"
...William Leonardi(ProjMgr) & Dave Briggs(SrMgrQUAL) pres., “Avid Case Study – Taking Your Molecule Through Process Validation"
Mar11: FY'19Q3 (qe 1-31-19) Financials & Conf. Call => CC Transcript: http://tinyurl.com/yy6dvjvc
Mar18-21: Drug, Chemical & Associated Tech. Assoc. (DCAT) Week, NYC

Apr2-4/Booth1159: Interphex Conf., NYC
...William Leonardi(ProjMgr) pres., “Avid Case Study – Taking Your Molecule Through Process Validation"
Apr8-12/Booth236: PEGS - The Essential Protein Eng. Summit, Boston
Jun3-6/Booth3149: BIO Intl. Convention, Philadelphia
~Jul15: FY'19Q4 (fye 4-30-19) Financials & Conf. Call
Aug12-15/Booth322: The Bioprocessing Summit, Boston
Sep9-12/Booth903: Biotech Week Boston
Oct16/Booth__: Outsourced Pharma, San Diego
Dec9-13/Booth__: Antibody Engineering & Therapeutics, San Diego

Quotes: Yahoo: Yahoo.com/CDMO Nasdaq: http://www.nasdaq.com/symbol/cdmo RT: http://www.nasdaq.com/symbol/cdmo/real-time
IR: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com, Tim Brons (Media) 415-675-7402 tbrons@vidasp.com

SEC:
Latest 10K 4-30-18 iss. 7-16-18 https://tinyurl.com/ydc8vew5 PR: https://tinyurl.com/y93fux9h (Cash 4-30-18=$42.3mm)
Latest 10Q 1-31-19 iss. 3-11-19 https://tinyurl.com/yxqjs7an PR: https://tinyurl.com/y2btdhqf (Cash 1-31-19=$27.8mm)
ALL SEC filings for CDMO: https://tinyurl.com/yc4zjyzv
CDMO's Corp. Bylaws (a/o 11-14-14): http://tinyurl.com/y8hsppea - Latest 14A/Proxy: https://tinyurl.com/y7qprpg9 (12-7-17)
Poison Pill adopted 3-16-06 for 10yrs: http://tinyurl.com/yvypvh 44-pg SEC filing: http://tinyurl.com/5m57ut BUNGLER explains in plain language: http://tinyurl.com/mft4nd6
...3-17-16 Poison Pill extended until 3-16-2021 https://tinyurl.com/y74glo2n (Form8A Amendment #1)

SHARES:
Shares O/S as of 3-4-19=56,074,509 - history since 4-2006: http://tinyurl.com/yy6dvjvc
...A/O 1-31-19: 3,301,498 stock options outstanding at a wgt.avg. exercise price of $7.51 (pg.14 10Q).
1-12-18: S-3 Shelf Registration filed for up to $125mm https://tinyurl.com/y9qtewpw
...2-20-18: Avid Raises ~$21.8M net, selling 10,294,445@$2.25 (underwriter: Wells Fargo) 8-K: https://tinyurl.com/ya3nenth 424B5: https://tinyurl.com/ycpshgxl
Total INST.+LARGE Holdings: 34,044,987 60.7% a/o 12-31-18 - See http://tinyurl.com/y23vydey

9 LARGEST SHAREHOLDERS a/o 12-31-18:
1. Tappan Street (Prasad Phatak): 4,854,100 8.7% (+337,993 a/o 12-31-18 13G: http://tinyurl.com/yxrpla3b )
2. Eastern Capital (Kenneth Dart): 4,300,992 7.7% (a/o 12-7-17 14A: https://tinyurl.com/y7qprpg9 acq. 10-2015)
3. Blackrock Inc. (Larry Fink): 3,580,783 6.4% (+3,834 q/e 12-31-18 Nasdaq Inst.; also 13G http://tinyurl.com/y3pmv4ko )
4. IsZo Capital Mgt. (Brian Sheehy): 3,489,698 6.2% (NEW a/o 12-31-18 Nasdaq Inst.; also 13G: http://tinyurl.com/y432zmgw )
5. Ronin Trading (John Stafford III+Roger Farley): 2,638,450 4.7% (a/o 4-17-18 13D: https://tinyurl.com/ycf7d2uk )
6. Vanguard Group: 2,431,396 4.3% (+101,198 q/e 12-31-18 Nasdaq Inst.)
7. Snyder Capital: 2,092,473 3.7% (+195,595 a/o 12-31-18 Nasdaq Inst.)
8. Altravue Capital: 1,319,968 2.4% (NEW a/o 12-31-18 Nasdaq Inst.)
9. Driehaus Capital: 773,276 1.4% (-108,615 a/o 12-31-18 Nasdaq Inst.)
Inst. Holdings (Nasdaq) - updated 45-days after each qtr-end: http://www.nasdaq.com/symbol/cdmo/institutional-holdings
INSIDER-Trans: https://tinyurl.com/ycpw4j9z  (formerly PPHM thru 2017: http://tinyurl.com/ypkow8 )
Short Interest, updated twice a month: https://www.nasdaq.com/symbol/cdmo/short-interest
A-T-M (At-The-Market) Sales 3/2009 - 7/14/17 ($272,500,000gr./34,869,747sh=$7.81/sh): http://tinyurl.com/yagmu2on
PPHM shares were 1:7 Reverse Split eff. 7-10-17 (315mm/$.606=>45mm/$4.24) http://tinyurl.com/yymtzcm9
PPHM shares were 1:5 Reverse Split eff. 10-19-09 (~237mm/$.64=>~47.4mm/$3.20) http://tinyurl.com/ykuw588
Potential Value: 9-19-2017: Catalent acquires CDMO Cook Pharmica for $950M ($179Msales x 5.3; EV/EBITDA=17.3) http://tinyurl.com/yd46m8py

AVID TEAM: https://avidbio.com/team - Open Jobs: https://avidbio.applicantpro.com/jobs
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s President and join PPHM’s BOD eff. 9-25-17 https://tinyurl.com/yddufw4s
11-29-17: Tracy L. Kinjerski (ex-CMC Biologics) joins Avid as VP/Bus.Operations https://tinyurl.com/yc4zenkc
2-23-18: CFO Paul Lytle voluntarily resigns eff. 5-24-18 (2-23-18 +90days), "CFO search underway" https://tinyurl.com/ybnjzbv6
5-8-18: Magnus Schroeder (ex-AGC Biologics) joins Avid as VP/Process Sciences https://tinyurl.com/y7tpswaw
5-29-18: Sandra C. Carbonneau (ex-Lonza) joins Avid as Dir./BusDev./EastCoast https://tinyurl.com/ybvrwn2l
7-16-18: Michael Faughnan (ex-Lonza & WuXi Biologics) joins Avid as Sr.Dir./BusDev./West Coast https://tinyurl.com/yaozdggz
7-16-18: Daniel Hart (ex-ENO Holdings) joins Avid as CFO https://tinyurl.com/ychz45p2
Profiles of all 7 BOD members & Compensation as of 11-28-17: https://tinyurl.com/y9lkl4q2
...Joseph Carleone/Chair, Richard Hancock, Gregory Sargen, Joel McComb, Roger Lias, Mark Bamforth, Patrick Walsh

Sept-Nov2017 PPHM/Form4’s for reconstituted 7-person BOD (Options Awarded):
...Joseph Carleone/Chairman, Richard Hancock, Gregory Sargen, Joel McComb: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Patrick Walsh: 75,000 @4.08, vesting monthly over 3yrs beg. 11-20-17
...Mark Bamforth: 75,000 @3.88, vesting monthly over 3yrs beg. 11-17-17
...Roger Lias: 150,000 @3.19, vesting in 4 equal annual installments beg. 9-25-18
OPEN MKT/PUBLIC OFFERING PURHASES BY BOD (Form 4's):
...Mark Bamforth pur. 50,000@$4.50 on 10-27-17 (open mkt) http://tinyurl.com/ya7pyyu5
...Mark Bamforth pur. 50,000@$2.25 on 2-15-18 (dir. public offering)  https://tinyurl.com/ybsn2gy6
...Joel McComb pur. 50,000@$2.25 on 2-15-18 (dir. public offering) https://tinyurl.com/ybx5saje SOLD 50,000@6.53 on Sept19-20 2018: https://tinyurl.com/y78acunh
...Joseph Carleone pur. 44,445@$2.25 on 2-15-18 (dir. public offering) https://tinyurl.com/ybskshrk
10-24-17: Peregrine Adds Patrick D. Walsh to BOD, "An Industry Veteran with 30+yrs Experience Leading Successful CDMO Org’s” http://tinyurl.com/y3jo2rv7
10-19-17: Peregrine Adds Mark R. Bamforth to BOD, "10yrs/Genzyme; 30yrs of biologics leadership experience, incl. founding 2 CDMOs" http://tinyurl.com/y6ydcaof

ANALYST COVERAGE: http://ir.avidbio.com/analyst-coverage
Janney Capital - Paul Knight (init. 6-25-18): Buy/PT=$10 https://www.janney.com Coverage: https://jms.bluematrix.com/docs/html/BLUE.html
H.C. Wainwright - Joseph Pantginis (init. 3-24-18) Buy/PT=$11 https://tinyurl.com/ya8hew4c Coverage: https://hcwco.com/services/research
First Analysis Securities - Steven Schwartz & Tracy Marshbanks (init. 3-13-18 https://tinyurl.com/yabgz2ff ): OverWgt/PT=$8
"In transition": Wells Fargo (init. 3-15-18 https://tinyurl.com/yae5bjn5 ): Outperform/PT=$3.50
"In transition": Noble Life Science Partners - Caroline Palomeque https://noblecapitalmarkets.com/life-science (init. 7-16-15); 12-12-17: Buy/PT=$10

FINANCIALS & BUSINESS DEV.:
3-11-19: CDMO's Revs & Burns By Qtr Table, FY07/Q1 thru FY19/Q3 (q/e 1-31-19): http://tinyurl.com/yy6dvjvc
......Avid FY19 (fye 4-30-19) revenues guidance: lower half of $51-55mm; committed backlog=$43mm at 1-31-2019.
4-24-18: ”In recent weeks, Avid has signed new agreements with 3 addl. undisclosed intl. drug dev. companies (that’s 4 thus far in CY2018)” https://tinyurl.com/y89whc8d
3-1-18: Acumen Pharm. selects Avid for Process Dev. & Mfg. of ACU193 (Alzheimer’s) https://tinyurl.com/y8jvwleq http://www.acumenpharm.com
2-21-18: Enzyvant selects Avid to commercially mfg. RVT-801 (Farber disease) https://tinyurl.com/yd5xhcx8 http://www.enzyvant.com
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...NOTE: 2-13-18: Oncologie Licenses Mologen’s immunotherapeutic ‘lefitolimod’ (TLR9 agonist) https://tinyurl.com/y9z54f4x “ONCOLOGIE is backed by top-tier intl. investors and has the objective to dev. novel personalized medicines in the field of immuno-oncology."
2-28-17: Avid & Cook (acq. by Catalent 12-2017 for $950M; $179Msales x 5.3; EV/EBITDA=17.3) remain Halozyme's 2 CMO's (“working to scale-up/validate/qualify Avid II/Myford for Roche collab.”): http://tinyurl.com/h75teta

FACILITIES: https://avidbio.com/services/#state-art-facilities
4-24-18: Avid adding Process Dev. Labs, upgrading capabilities (in phases; total will be >6000sq; 1st one ready Q3CY18/Jul-Sep'18) https://tinyurl.com/y89whc8d
5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L". http://tinyurl.com/ky7bmu4
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17: http://tinyurl.com/mrl34uk
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
6-2-16: Corp.Update – Avid Expansion & Drug Development - http://tinyurl.com/zvmhqmr
3-7-16/Avid II: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs) http://tinyurl.com/y5jmfpo3
12-10-15/Avid II: Avid Expansion into MYFORD Facility now GMP-run ready (potential +$40mm sales) - contemplating further expansion http://tinyurl.com/y539yut4
12-10-14: Avid to Double Mfg. Capacity(“Myford Expansion”) http://tinyurl.com/y2sqoy2u & http://tinyurl.com/kmdgq8t



PRESENTATIONS & ARTICLES: http://ir.avidbio.com/events.cfm
10-25-18/BioPharma: Roger Lias Interview, “Avid expansion to Triple Process Dev. Capacity” https://tinyurl.com/ybtuk29m
Sept2018/BioTechWEEK: Tracy Kinjerski (VP/BusOP) interview: Avid’s differentiators (6mins.) https://www.youtube.com/watch?v=x3tzo4pZivk
1-29-18: NobleCon14 - 14th Annual Inv. Conf., Ft.Laud. => Roger Lias' webcast/slideshow https://tinyurl.com/yanwk9yo
11-15-17/Outsourcing-Pharma: “How This R&D Company (Peregrine) is Transitioning to a Pure-Play CDMO: ‘Opportunities Are Almost Endless’" - Recap of interviews with Steve King & Avid Pres. Roger Lias http://tinyurl.com/y7dv9faz

CONFERENCE CALLS & ASM's:
3-11-19: Qtly. Conf. Call (Lias/Hart) PR & Transcript http://tinyurl.com/yy6dvjvc
12-3-18: Qtly. Conf. Call (Lias/Hart//Kinjerski) PR & Transcript https://tinyurl.com/y9n374kp
10-4-18: ASM/2018 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Report https://tinyurl.com/yctfzhlb
9-10-18: Qtly. Conf. Call (Lias/Hart) PR & Transcript https://tinyurl.com/y8oc6hx8
...Roger Lias, "During the qtr, we advanced the projects of our existing active clients and continue to engage with numerous potential new customers."
7-16-18: Qtly. Conf. Call (Lias/Kinjerski) PR & Transcript https://tinyurl.com/yaozdggz
...Roger Lias, “In a short period, we’ve established a targeted business dev. operation that is actively providing visibility for Avid Bioservices within our fast growing but competitive marketplace.”
3-12-18: Qtly. Conf. Call (Lias/Kinjerski/Lytle) PR & Transcript https://tinyurl.com/yakdl4wj
...Roger Lias, ”I'm pleased to be able to report that in a very short period of time we've generated significant interest from both emerging & growth biopharmaceutical players and from pharmaceutical multinationals. I'm confident that the plan we're executing will drive a considerable increase in backlog and the opportunity to further enhance capacity utilization in the future.”
......From the 3-12-18 PR: “At present, we are in late-stage negotiations with several potential new customers and expect to announce the executed agreements before the end of the FY[4-30-18].”
1-18-18: ASM/2017 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Reports https://tinyurl.com/yca6enbr 12-7-17 PROXY/14A: https://tinyurl.com/y7qprpg9
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6
...Roger Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
9-11-17: Qtly. Conf. Call (King/Lias/Lytle) Transcript http://tinyurl.com/y9y8qdac
...Steve King: “For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering & eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment & expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.”
7-14-17: Qtly. Conf. Call (King/Shan/Lytle) Transcript http://tinyurl.com/yb4wulvu
...Steve King: “We are seriously considering the possibility of separating our 2 distinct businesses, Avid and R&D/PS-Targeting.”
3-13-17: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/grhwjvy
...Steve King: “We believe the recent improvement of stock price is a growing recognition of the value of Avid, and having the full value of the Avid business reflected in our stock price is a top priority.”
12-12-16: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/hhn4gga
...Steve King: “Our goal is to bring the overall company to profitability within the next 18mos. We believe just the value of Avid Bioservices is far greater than our current market cap and is only growing in value."
10-13-16 ASM/2016: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast: http://tinyurl.com/jx7ouay



Feb. 2018: Peregrine Pharmaceuticals completed its Mid’17-Early’18 Transition to a Pure-Play CDMO
(Contract Development & Manufacturing Organization), Avid Bioservices, Inc. - CEO: Roger Lias.

**FULL PPHM=>CDMO Transition History (Ronin/SWIM): https://tinyurl.com/ybqvzwhg
1-8-17: Peregrine chgs. name to “Avid Bioservices, Inc.”; new ticker: “CDMO” (+CDMOP) https://tinyurl.com/y8vhjow4
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...12-13-18/8-K: Overview of Oncologie sale: https://tinyurl.com/yab9c6cr
NOTE: “PS-targeting Exosome tech. not included; back to UTSW", see: https://tinyurl.com/yakdl4wj

Click here for an ARCHIVE of the History of Peregrine’s Anti-PS/Bavituximab Platform - MOA, Trials, and Activity over the years, from early 2000’s thru 2017, prior to being Sold to ONCOLOGIE:
https://tinyurl.com/y8pq4rhc
Of Interest (post Oncologie Sale):
4-20-18/AACR’18: MSKCC(LudwigCC) Tweets about 2 WolchokLAB/”PPHM” Anti-PS Posters https://tinyurl.com/ycgjhvqa
4-26-18: New Bavi+Keytruda/LIVER Ph2 IST Trial, Sponsor=UTSW, Collab=MERCK https://tinyurl.com/y7fd9vdb
6-7-18: Oncologie Obtains $16.5M Seed Funding Led by Pivotal bioVenture Partners China Fund https://tinyurl.com/ybrrbgg7
6-7-18/BioCentury: Laura Benjamin states, “Oncologie plans to begin a trial mid-summer '18 evaluating Bavi to treat HCC and a P-O-C trial in Gastric cancer in 1Q19/2Q19.” https://tinyurl.com/ycb8r7sm
12-3-18: During q/e 10-31-18, Avid sold remaining legacy R&D asset, r84(anti-VEGF), to Oncologie for $1.0M upfront. Avid is eligible to receive up to an addl. $21M in dev/reg./comm. milestones, and low to mid-single digit royalties on net sales upon commercialization of products utilizing r84 https://tinyurl.com/y9n374kp

CDMO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CDMO News: Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 03/06/2019 04:05:00 PM
CDMO News: Avid Bioservices To Report Financial Results For Third Quarter Of Fiscal Year 2019 After Market Close On March 11, 2019 03/04/2019 08:05:00 AM
CDMO News: Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2019 and Recent Developments 12/10/2018 04:05:00 PM
CDMO News: Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 12/05/2018 04:05:00 PM
CDMO News: Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2019 After Market Close on December 10, 2018 12/03/2018 08:05:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#329801  Sticky Note 3-11-19 Qtly CC-Transcript, PR(Q3FY19/qe1-31-19), Avid Revs History Table cjgaddy 03/12/19 12:35:21 PM
#329621  Sticky Note Total INST.+LARGE Holdings now 34,044,987 60.7% (12-31-18) cjgaddy 02/15/19 10:52:23 AM
#329252  Sticky Note 10-4-18/2018 ASM: Roger Lias’ Slideshow & Attendee Report cjgaddy 11/20/18 01:57:23 PM
#324889  Sticky Note ARCHIVE of Peregrine’s Anti-PS/Bavituximab Platform - MOA, Trials, cjgaddy 02/17/18 08:45:37 AM
#324848  Sticky Note 2-12-18: Avid Sells PS/IP to Oncologie; CDMO-Transition History cjgaddy 02/16/18 09:24:50 AM
#330166   just my opinion, but I predict a next JCNJ 04/24/19 04:22:23 PM
#330165   Nice bounce off morning low pandb5298 04/24/19 11:15:56 AM
#330164   Wash, rinse, repeat............ Price spikes without news....shorts rush drontle2 04/24/19 09:50:45 AM
#330163   Down .50 on 40/shares....will Clay Pidgeon show up next! patientlywaiting 04/24/19 08:32:04 AM
#330162   Chart looks great. Added a bit today. stoneroad 04/23/19 10:12:25 PM
#330161   How funny. Someone posted a bit ago JCNJ 04/23/19 05:51:43 PM
#330160   I guess not! So, is today’s action drontle2 04/23/19 04:42:46 PM
#330159   Thank you Golfho, well thought post (as always) tradero 04/23/19 01:36:23 PM
#330158   9K blocking at the ask of 4.62. cheynew 04/23/19 01:15:36 PM
#330157   Golfho - you are and always have been epcjmc 04/23/19 12:41:49 PM
#330156   I’d like to see this break 4.59, the cheynew 04/23/19 11:38:35 AM
#330155   One more optimistic thought. horselover45 04/23/19 11:37:36 AM
#330154   How about thought that there might not be horselover45 04/23/19 11:12:06 AM
#330153   Agreed. cheynew 04/23/19 11:11:30 AM
#330152   Need volume and lots of it or just geocappy1 04/23/19 11:07:14 AM
#330151   Seems to be picking up. 20K buy cheynew 04/23/19 11:00:04 AM
#330150   Any thoughts on this anemic volume? geocappy1 04/23/19 10:07:26 AM
#330149   Nice work Golfho! It's good to see someone eb0783 04/22/19 04:48:43 PM
#330148   Hi Cheynew... golfho 04/22/19 04:47:05 PM
#330147   I was looking through old prs and saw cheynew 04/22/19 03:35:41 PM
#330146   14 jobs open, down from 17 listed last week. cheynew 04/22/19 03:29:14 PM
#330145   Some interesting facts: golfho 04/22/19 02:03:03 PM
#330144   Ronin Hedge Group brought one of the Best biopharm 04/22/19 07:45:25 AM
#330142  Restored Good Evening ifu, have you accounted for an Excelsiortruth 04/21/19 11:57:52 AM
#330141   SUNRISE” has 11 authors: Lead author is PPHM’s biopharm 04/21/19 11:40:38 AM
#330140   So far for the 3/31 qtr with only cheynew 04/21/19 09:44:18 AM
#330139   Good Morning patently waiting, what do you Excelsiortruth 04/20/19 09:29:11 PM
#330138   "Enjoy seeing Stafford squirm." patientlywaiting 04/20/19 06:32:22 PM
#330137   You can put me in the unbelievably bitter camp Bluerinse 04/19/19 10:51:38 PM
#330136   Good morning IMP, purposefully misleading is more Excelsiortruth 04/19/19 10:40:15 PM
#330135   There is such a huge dispersion between the The Imp 04/19/19 07:06:51 PM
#330134   Agreed.. .probably the best we could ever hope for! Imo Bluerinse 04/19/19 03:46:58 PM
#330133   BAVI-SCHEME = PONZI-SCHEME and the previous PPHM BOD InternetForumUser 04/19/19 12:42:29 PM
#330132   At $10/share, I would be out of this InternetForumUser 04/19/19 12:39:38 PM
#330131   Any reason WHY „they“ would keep it down? vinmantoo 04/19/19 11:04:11 AM
#330130   Check the posts, there all there from the djohn 04/18/19 05:26:57 PM
#330129   Depends on what level of news arrives and biopharm 04/18/19 04:38:13 PM
#330128   Any reason WHY „they“ would keep it down? Wernaaa 04/18/19 04:02:26 PM
#330127   Stafford owns over 350,000 shares of Genmark Diagnostics biopharm 04/18/19 03:33:28 PM
#330126   Yes, Big Pharma has been missing something for biopharm 04/18/19 03:29:27 PM
#330125   djohn, Really?? G-no 04/18/19 02:55:15 PM
#330124   ET CHEVYGUY 04/18/19 12:54:24 PM
#330123   Who is the sidekick? The Imp 04/18/19 12:49:15 PM
#330122   Good Morning G, I was kidding about you djohn 04/18/19 12:42:12 PM
#330121   If you have any kids or grandkids or The Imp 04/18/19 12:32:30 PM
#330120   Where will the share price go when Avid pandb5298 04/18/19 12:10:40 PM
#330119   Hi Imp G-no 04/18/19 11:50:12 AM
#330118   If anyone with half a brain ever wanted The Imp 04/18/19 11:30:56 AM
#330117   Good Morning djohn. G-no 04/18/19 11:20:32 AM
#330116   2205 April $5 calls expire worthless tomorrow. cheynew 04/18/19 11:18:28 AM
PostSubject